BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22451227)

  • 1. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.
    Podbielska M; Krotkiewski H; Hogan EL
    Neurochem Res; 2012 Jun; 37(6):1154-69. PubMed ID: 22451227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
    Takabe K; Paugh SW; Milstien S; Spiegel S
    Pharmacol Rev; 2008 Jun; 60(2):181-95. PubMed ID: 18552276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipids: important players in multiple sclerosis.
    Halmer R; Walter S; Faßbender K
    Cell Physiol Biochem; 2014; 34(1):111-8. PubMed ID: 24977485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.
    Berdyshev EV; Gorshkova I; Skobeleva A; Bittman R; Lu X; Dudek SM; Mirzapoiazova T; Garcia JG; Natarajan V
    J Biol Chem; 2009 Feb; 284(9):5467-77. PubMed ID: 19119142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.
    Miller LG; Young JA; Ray SK; Wang G; Purohit S; Banik NL; Dasgupta S
    Neurochem Res; 2017 Oct; 42(10):2755-2768. PubMed ID: 28474276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
    Proia RL; Hla T
    J Clin Invest; 2015 Apr; 125(4):1379-87. PubMed ID: 25831442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T; Billich A; Brinkmann V
    Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
    Huwiler A; Pfeilschifter J
    Curr Pharm Des; 2006; 12(35):4625-35. PubMed ID: 17168766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders.
    Czubowicz K; Jęśko H; Wencel P; Lukiw WJ; Strosznajder RP
    Mol Neurobiol; 2019 Aug; 56(8):5436-5455. PubMed ID: 30612333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
    Miron VE; Ludwin SK; Darlington PJ; Jarjour AA; Soliven B; Kennedy TE; Antel JP
    Am J Pathol; 2010 Jun; 176(6):2682-94. PubMed ID: 20413685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.
    Dasgupta S; Ray SK
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
    Tian YL; Jin J; Wang XJ
    Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M; Amor S
    Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles for lysophospholipid S1P receptors in multiple sclerosis.
    Noguchi K; Chun J
    Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of sphingosine 1-phosphate on functions of T cell - review].
    Huang WR; Wang LS; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.